FCM
MRTX

Frontier Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Frontier Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-43,020
Closed -$3.15M – 306
2019
Q1 		$3.15M Buy
+43,020
New +$2.93M 0.02% 276

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Frontier Capital Management's MRTX Position: Q2 2019 in Review

Frontier Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2019, closing a stake of 43,020 shares — an estimated $3.15M sold.

Frontier Capital Management first reported a position in MRTX in Q1 2019 and held it in 1 quarter. The position peaked at $3.15M in Q1 2019. 172 funds tracked by Wall St. Rank hold MRTX as of Q2 2019.

  • Frontier Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Frontier Capital Management sold 43,020 Mirati Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $3.15M.
  • Frontier Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Frontier Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $3.15M in Q1 2019.
  • 172 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Frontier Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.